Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 53 entries
Sorted by: Best Match Show Resources per page
Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group.

Journal of medical genetics

Aronson M, Colas C, Shuen A, Hampel H, Foulkes WD, Baris Feldman H, Goldberg Y, Muleris M, Wolfe Schneider K, McGee RB, Jasperson K, Rangaswami A, Brugieres L, Tabori U.
PMID: 33622763
J Med Genet. 2021 Feb 23; doi: 10.1136/jmedgenet-2020-107627. Epub 2021 Feb 23.

BACKGROUND: Constitutional mismatch repair deficiency syndrome (CMMRD) is the most aggressive cancer predisposition syndrome associated with multiorgan cancers, often presenting in childhood. There is variability in age and presentation of cancers and benign manifestations mimicking neurofibromatosis type 1. Genetic...

Cite
Aronson M, Colas C, Shuen A, et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J Med Genet. 2021;doi: 10.1136/jmedgenet-2020-107627.
Aronson, M., Colas, C., Shuen, A., Hampel, H., Foulkes, W. D., Baris Feldman, H., Goldberg, Y., Muleris, M., Wolfe Schneider, K., McGee, R. B., Jasperson, K., Rangaswami, A., Brugieres, L., & Tabori, U. (2021). Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. Journal of medical genetics, . https://doi.org/10.1136/jmedgenet-2020-107627
Aronson, Melyssa, et al. "Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group." Journal of medical genetics vol. (2021). doi: https://doi.org/10.1136/jmedgenet-2020-107627
Aronson M, Colas C, Shuen A, Hampel H, Foulkes WD, Baris Feldman H, Goldberg Y, Muleris M, Wolfe Schneider K, McGee RB, Jasperson K, Rangaswami A, Brugieres L, Tabori U. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. J Med Genet. 2021 Feb 23; doi: 10.1136/jmedgenet-2020-107627. Epub 2021 Feb 23. PMID: 33622763.
Copy Download .nbib Format: NLM
Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient.

Respiratory medicine and research

Glorion M, De Wolf J, Zuber B, Cassiano F, Preau S, Brun AL, Cohen J, Tachon G, Neuville M, Brugière O, Picard C, Beaumont-Azuar L, Fessler J, Jacqmin S, Pricopi C, Chapelier A, Cuquemelle E, Parquin F, Magnan A, Roux A, Le Guen M, Sage E, Cerf C.
PMID: 34433119
Respir Med Res. 2021 Nov;80:100851. doi: 10.1016/j.resmer.2021.100851. Epub 2021 Aug 08.

No abstract available.

Cite
Glorion M, De Wolf J, Zuber B, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient. Respir Med Res. 2021;80:100851doi: 10.1016/j.resmer.2021.100851.
Glorion, M., De Wolf, J., Zuber, B., Cassiano, F., Preau, S., Brun, A. L., Cohen, J., Tachon, G., Neuville, M., Brugière, O., Picard, C., Beaumont-Azuar, L., Fessler, J., Jacqmin, S., Pricopi, C., Chapelier, A., Cuquemelle, E., Parquin, F., Magnan, A., Roux, A., Le Guen, M., Sage, E., & Cerf, C. (2021). Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient. Respiratory medicine and research, 80100851. https://doi.org/10.1016/j.resmer.2021.100851
Glorion, M, et al. "Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient." Respiratory medicine and research vol. 80 (2021): 100851. doi: https://doi.org/10.1016/j.resmer.2021.100851
Glorion M, De Wolf J, Zuber B, Cassiano F, Preau S, Brun AL, Cohen J, Tachon G, Neuville M, Brugière O, Picard C, Beaumont-Azuar L, Fessler J, Jacqmin S, Pricopi C, Chapelier A, Cuquemelle E, Parquin F, Magnan A, Roux A, Le Guen M, Sage E, Cerf C. Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient. Respir Med Res. 2021 Nov;80:100851. doi: 10.1016/j.resmer.2021.100851. Epub 2021 Aug 08. PMID: 34433119; PMCID: PMC8349363.
Copy Download .nbib Format: NLM
Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Moulin F, Dumontier S, Saulnier P, Chachaty E, Loubeyre C, Brugières L, Andremont A.
PMID: 11866843
Clin Microbiol Infect. 1996 Feb;2(3):192-201. doi: 10.1016/s1198-743x(14)65142-9.

OBJECTIVE: To study epidemiologic features of and risk factors for intestinal colonization and infection by vancomycin-resistant enterococci (VRE) in cancer patients. METHODS: During a 41-month period, over 7600 fecal samples and all samples from sterile sites from hospitalized cancer...

Cite
Moulin F, Dumontier S, Saulnier P, et al. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect. 1996;2(3):192-201doi: 10.1016/s1198-743x(14)65142-9.
Moulin, F., Dumontier, S., Saulnier, P., Chachaty, E., Loubeyre, C., Brugières, L., & Andremont, A. (1996). Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2(3), 192-201. https://doi.org/10.1016/s1198-743x(14)65142-9
Moulin, Florence, et al. "Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients." Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 2,3 (1996): 192-201. doi: https://doi.org/10.1016/s1198-743x(14)65142-9
Moulin F, Dumontier S, Saulnier P, Chachaty E, Loubeyre C, Brugières L, Andremont A. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect. 1996 Feb;2(3):192-201. doi: 10.1016/s1198-743x(14)65142-9. PMID: 11866843.
Copy Download .nbib Format: NLM
MicroRNA therapy inhibits hepatoblastoma growth .

Hepatology communications

Indersie E, Lesjean S, Hooks KB, Sagliocco F, Ernault T, Cairo S, Merched-Sauvage M, Rullier A, Le Bail B, Taque S, Grotzer M, Branchereau S, Guettier C, Fabre M, Brugières L, Hagedorn M, Buendia MA, Grosset CF.
PMID: 29404451
Hepatol Commun. 2017 Apr 06;1(2):168-183. doi: 10.1002/hep4.1029. eCollection 2017 Apr.

Hepatoblastoma (HBL) is the most common pediatric liver cancer. In this malignant neoplasm, beta-catenin protein accumulates and increases Wnt signaling due to recurrent activating mutations in the catenin-beta 1 (

Cite
Indersie E, Lesjean S, Hooks KB, et al. MicroRNA therapy inhibits hepatoblastoma growth . Hepatol Commun. 2017;1(2):168-183doi: 10.1002/hep4.1029.
Indersie, E., Lesjean, S., Hooks, K. B., Sagliocco, F., Ernault, T., Cairo, S., Merched-Sauvage, M., Rullier, A., Le Bail, B., Taque, S., Grotzer, M., Branchereau, S., Guettier, C., Fabre, M., Brugières, L., Hagedorn, M., Buendia, M. A., & Grosset, C. F. (2017). MicroRNA therapy inhibits hepatoblastoma growth . Hepatology communications, 1(2), 168-183. https://doi.org/10.1002/hep4.1029
Indersie, Emilie, et al. "MicroRNA therapy inhibits hepatoblastoma growth ." Hepatology communications vol. 1,2 (2017): 168-183. doi: https://doi.org/10.1002/hep4.1029
Indersie E, Lesjean S, Hooks KB, Sagliocco F, Ernault T, Cairo S, Merched-Sauvage M, Rullier A, Le Bail B, Taque S, Grotzer M, Branchereau S, Guettier C, Fabre M, Brugières L, Hagedorn M, Buendia MA, Grosset CF. MicroRNA therapy inhibits hepatoblastoma growth . Hepatol Commun. 2017 Apr 06;1(2):168-183. doi: 10.1002/hep4.1029. eCollection 2017 Apr. PMID: 29404451; PMCID: PMC5721429.
Copy Download .nbib Format: NLM
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome.

Frontiers in immunology

Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A.
PMID: 29375549
Front Immunol. 2018 Jan 11;8:1841. doi: 10.3389/fimmu.2017.01841. eCollection 2017.

Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term survival after lung transplantation. Identifying predictors of BOS is essential to prevent the progression of dysfunction before irreversible damage occurs. By using a...

Cite
Danger R, Royer PJ, Reboulleau D, et al. Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. Front Immunol. 2018;8:1841doi: 10.3389/fimmu.2017.01841.
Danger, R., Royer, P. J., Reboulleau, D., Durand, E., Loy, J., Tissot, A., Lacoste, P., Roux, A., Reynaud-Gaubert, M., Gomez, C., Kessler, R., Mussot, S., Dromer, C., Brugière, O., Mornex, J. F., Guillemain, R., Dahan, M., Knoop, C., Botturi, K., Foureau, A., Pison, C., Koutsokera, A., Nicod, L. P., Brouard, S., Magnan, A. (2017). Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. Frontiers in immunology, 81841. https://doi.org/10.3389/fimmu.2017.01841
Danger, Richard, et al. "Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome." Frontiers in immunology vol. 8 (2017): 1841. doi: https://doi.org/10.3389/fimmu.2017.01841
Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A. Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. Front Immunol. 2018 Jan 11;8:1841. doi: 10.3389/fimmu.2017.01841. eCollection 2017. PMID: 29375549; PMCID: PMC5768645.
Copy Download .nbib Format: NLM
[No title available]

Oncoimmunology

Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, Martin Y, Imbeaud S, Letouzé E, Rebouissou S, Branchereau S, Taque S, Chardot C, Guettier C, Scoazec JY, Fabre M, Brugières L, Zucman-Rossi J.
PMID: 31069152
Oncoimmunology. 2019 Mar 28;8(6):e1583547. doi: 10.1080/2162402X.2019.1583547. eCollection 2019.

Hepatoblastoma (HB) is the most common liver cancer in children. We aimed to characterize HB related to

Cite
Morcrette G, Hirsch TZ, Badour E, et al. . Oncoimmunology. 2019;8(6):e1583547doi: 10.1080/2162402X.2019.1583547.
Morcrette, G., Hirsch, T. Z., Badour, E., Pilet, J., Caruso, S., Calderaro, J., Martin, Y., Imbeaud, S., Letouzé, E., Rebouissou, S., Branchereau, S., Taque, S., Chardot, C., Guettier, C., Scoazec, J. Y., Fabre, M., Brugières, L., & Zucman-Rossi, J. (2019). . Oncoimmunology, 8(6), e1583547. https://doi.org/10.1080/2162402X.2019.1583547
Morcrette, Guillaume, et al. "." Oncoimmunology vol. 8,6 (2019): e1583547. doi: https://doi.org/10.1080/2162402X.2019.1583547
Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, Martin Y, Imbeaud S, Letouzé E, Rebouissou S, Branchereau S, Taque S, Chardot C, Guettier C, Scoazec JY, Fabre M, Brugières L, Zucman-Rossi J. . Oncoimmunology. 2019 Mar 28;8(6):e1583547. doi: 10.1080/2162402X.2019.1583547. eCollection 2019. PMID: 31069152; PMCID: PMC6492969.
Copy Download .nbib Format: NLM
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma.

Neuro-oncology advances

Pereira V, Torrejon J, Kariyawasam D, Berlanga P, Guerrini-Rousseau L, Ayrault O, Varlet P, Tauziède-Espariat A, Puget S, Bolle S, Beccaria K, Blauwblomme T, Brugières L, Grill J, Geoerger B, Dufour C, Abbou S.
PMID: 34409296
Neurooncol Adv. 2021 Jul 07;3(1):vdab097. doi: 10.1093/noajnl/vdab097. eCollection 2021.

BACKGROUND: Smoothened inhibitors (SMOi) have shown activity in Sonic Hedgehog (SHH) medulloblastoma, however this therapeutic class was not developed in children due to severe effects reported on growth. We hereby report long-term follow-up of young patients treated with SMOi...

Cite
Pereira V, Torrejon J, Kariyawasam D, et al. Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neurooncol Adv. 2021;3(1):vdab097doi: 10.1093/noajnl/vdab097.
Pereira, V., Torrejon, J., Kariyawasam, D., Berlanga, P., Guerrini-Rousseau, L., Ayrault, O., Varlet, P., Tauziède-Espariat, A., Puget, S., Bolle, S., Beccaria, K., Blauwblomme, T., Brugières, L., Grill, J., Geoerger, B., Dufour, C., & Abbou, S. (2021). Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neuro-oncology advances, 3(1), vdab097. https://doi.org/10.1093/noajnl/vdab097
Pereira, Victor, et al. "Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma." Neuro-oncology advances vol. 3,1 (2021): vdab097. doi: https://doi.org/10.1093/noajnl/vdab097
Pereira V, Torrejon J, Kariyawasam D, Berlanga P, Guerrini-Rousseau L, Ayrault O, Varlet P, Tauziède-Espariat A, Puget S, Bolle S, Beccaria K, Blauwblomme T, Brugières L, Grill J, Geoerger B, Dufour C, Abbou S. Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neurooncol Adv. 2021 Jul 07;3(1):vdab097. doi: 10.1093/noajnl/vdab097. eCollection 2021. PMID: 34409296; PMCID: PMC8367281.
Copy Download .nbib Format: NLM
Malignant tumours of the foot and ankle.

EFORT open reviews

Mascard E, Gaspar N, Brugières L, Glorion C, Pannier S, Gomez-Brouchet A.
PMID: 28630763
EFORT Open Rev. 2017 May 11;2(5):261-271. doi: 10.1302/2058-5241.2.160078. eCollection 2017 May.

Most of tumours of the foot are tumour-like (synovial cyst, foreign body reactions and epidermal inclusion cyst) or benign conditions (tenosynovial giant cells tumours, planta fibromatosis). Malignant tumours of the soft-tissue and skeleton are very rare in the foot...

Cite
Mascard E, Gaspar N, Brugières L, et al. Malignant tumours of the foot and ankle. EFORT Open Rev. 2017;2(5):261-271doi: 10.1302/2058-5241.2.160078.
Mascard, E., Gaspar, N., Brugières, L., Glorion, C., Pannier, S., & Gomez-Brouchet, A. (2017). Malignant tumours of the foot and ankle. EFORT open reviews, 2(5), 261-271. https://doi.org/10.1302/2058-5241.2.160078
Mascard, E, et al. "Malignant tumours of the foot and ankle." EFORT open reviews vol. 2,5 (2017): 261-271. doi: https://doi.org/10.1302/2058-5241.2.160078
Mascard E, Gaspar N, Brugières L, Glorion C, Pannier S, Gomez-Brouchet A. Malignant tumours of the foot and ankle. EFORT Open Rev. 2017 May 11;2(5):261-271. doi: 10.1302/2058-5241.2.160078. eCollection 2017 May. PMID: 28630763; PMCID: PMC5467685.
Copy Download .nbib Format: NLM
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Clinical sarcoma research

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.
PMID: 27315524
Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone...

Cite
Kager L, Whelan J, Dirksen U, et al. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 2016;6:3doi: 10.1186/s13569-016-0043-5.
Kager, L., Whelan, J., Dirksen, U., Hassan, B., Anninga, J., Bennister, L., Bovée, J. V. M. G., Brennan, B., Broto, J. M., Brugières, L., Cleton-Jansen, A. M., Copland, C., Dutour, A., Fagioli, F., Ferrari, S., Fiocco, M., Fleuren, E., Gaspar, N., Gelderblom, H., Gerrand, C., Gerß, J., Gonzato, O., van der Graaf, W., Hecker-Nolting, S., Herrero-Martín, D., Klco-Brosius, S., Kovar, H., Ladenstein, R., Lancia, C., LeDeley, M. C., McCabe, M. G., Metzler, M., Myklebost, O., Nathrath, M., Picci, P., Potratz, J., Redini, F., Richter, G. H. S., Reinke, D., Rutkowski, P., Scotlandi, K., Strauss, S., Thomas, D., Tirado, O. M., Tirode, F., Vassal, G., & Bielack, S. S. (2016). The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clinical sarcoma research, 63. https://doi.org/10.1186/s13569-016-0043-5
Kager, Leo, et al. "The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report." Clinical sarcoma research vol. 6 (2016): 3. doi: https://doi.org/10.1186/s13569-016-0043-5
Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016. PMID: 27315524; PMCID: PMC4794847.
Copy Download .nbib Format: NLM
Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study.

BMJ open

Chappuy H, Bouazza N, Minard-Colin V, Patte C, Brugières L, Landman-Parker J, Auvrignon A, Davous D, Pacquement H, Orbach D, Tréluyer JM, Doz F.
PMID: 23793670
BMJ Open. 2013 May 28;3(5). doi: 10.1136/bmjopen-2013-002733.

OBJECTIVES: To analyse the parental understanding of informed consent information in first-line randomised clinical trials (RCTs) including children with malignant solid tumours and to assess parents' needs for decision-making.DESIGN: Observational prospective study.SETTING: 3 paediatric oncology centres in the Parisian...

Cite
Chappuy H, Bouazza N, Minard-Colin V, et al. Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ Open. 2013;3(5)doi: 10.1136/bmjopen-2013-002733.
Chappuy, H., Bouazza, N., Minard-Colin, V., Patte, C., Brugières, L., Landman-Parker, J., Auvrignon, A., Davous, D., Pacquement, H., Orbach, D., Tréluyer, J. M., & Doz, F. (2013). Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ open, 3(5), . https://doi.org/10.1136/bmjopen-2013-002733
Chappuy, Hélène, et al. "Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study." BMJ open vol. 3,5 (2013). doi: https://doi.org/10.1136/bmjopen-2013-002733
Chappuy H, Bouazza N, Minard-Colin V, Patte C, Brugières L, Landman-Parker J, Auvrignon A, Davous D, Pacquement H, Orbach D, Tréluyer JM, Doz F. Parental comprehension of the benefits/risks of first-line randomised clinical trials in children with solid tumours: a two-stage cross-sectional interview study. BMJ Open. 2013 May 28;3(5). doi: 10.1136/bmjopen-2013-002733. PMID: 23793670; PMCID: PMC3657641.
Copy Download .nbib Format: NLM
Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey.

ESMO open

Li CK, Dalvi R, Yonemori K, Ariffin H, Lyu CJ, Farid M, Gonzales-Santos JRN, Zhou Q, Bielack S, Brugieres L, Blondeel A, Essiaf S, Peccatori FA, Jezdic S, Stark DP, Douillard JY, Saloustros E, Mountzios G.
PMID: 31231565
ESMO Open. 2019 Jun 06;4(3):e000467. doi: 10.1136/esmoopen-2018-000467. eCollection 2019.

BACKGROUND: Adolescents and young adults (AYAs) with cancer require dedicated management encompassing both adult and paediatric cancer services. Following a European survey, the European Society for Medical Oncology, the European Society for Paediatric Oncology and the Asian continental branch...

Cite
Li CK, Dalvi R, Yonemori K, et al. Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO Open. 2019;4(3):e000467doi: 10.1136/esmoopen-2018-000467.
Li, C. K., Dalvi, R., Yonemori, K., Ariffin, H., Lyu, C. J., Farid, M., Gonzales-Santos, J. R. N., Zhou, Q., Bielack, S., Brugieres, L., Blondeel, A., Essiaf, S., Peccatori, F. A., Jezdic, S., Stark, D. P., Douillard, J. Y., Saloustros, E., & Mountzios, G. (2019). Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO open, 4(3), e000467. https://doi.org/10.1136/esmoopen-2018-000467
Li, Chi Kong, et al. "Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey." ESMO open vol. 4,3 (2019): e000467. doi: https://doi.org/10.1136/esmoopen-2018-000467
Li CK, Dalvi R, Yonemori K, Ariffin H, Lyu CJ, Farid M, Gonzales-Santos JRN, Zhou Q, Bielack S, Brugieres L, Blondeel A, Essiaf S, Peccatori FA, Jezdic S, Stark DP, Douillard JY, Saloustros E, Mountzios G. Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO Open. 2019 Jun 06;4(3):e000467. doi: 10.1136/esmoopen-2018-000467. eCollection 2019. PMID: 31231565; PMCID: PMC6555609.
Copy Download .nbib Format: NLM
Micromolecular methods for diagnosis and therapeutic strategy: a case study.

Oncotarget

Elbouchtaoui M, Tengher I, Miquel C, Brugière C, Benbara A, Zelek L, Ziol M, Bouhidel F, Janin A, Bousquet G, Leboeuf C.
PMID: 29854320
Oncotarget. 2018 Apr 27;9(32):22862-22869. doi: 10.18632/oncotarget.25161. eCollection 2018 Apr 27.

An intraductal carcinoma, 55 mm across, was diagnosed on a total mastectomy in a 45-year-old woman. The 2 micro-invasive areas found were too small for reliable immunostainings for estrogen, progesterone, and HER2 receptors. In the sentinel lymph-node, a subcapsular...

Cite
Elbouchtaoui M, Tengher I, Miquel C, et al. Micromolecular methods for diagnosis and therapeutic strategy: a case study. Oncotarget. 2018;9(32):22862-22869doi: 10.18632/oncotarget.25161.
Elbouchtaoui, M., Tengher, I., Miquel, C., Brugière, C., Benbara, A., Zelek, L., Ziol, M., Bouhidel, F., Janin, A., Bousquet, G., & Leboeuf, C. (2018). Micromolecular methods for diagnosis and therapeutic strategy: a case study. Oncotarget, 9(32), 22862-22869. https://doi.org/10.18632/oncotarget.25161
Elbouchtaoui, Morad, et al. "Micromolecular methods for diagnosis and therapeutic strategy: a case study." Oncotarget vol. 9,32 (2018): 22862-22869. doi: https://doi.org/10.18632/oncotarget.25161
Elbouchtaoui M, Tengher I, Miquel C, Brugière C, Benbara A, Zelek L, Ziol M, Bouhidel F, Janin A, Bousquet G, Leboeuf C. Micromolecular methods for diagnosis and therapeutic strategy: a case study. Oncotarget. 2018 Apr 27;9(32):22862-22869. doi: 10.18632/oncotarget.25161. eCollection 2018 Apr 27. PMID: 29854320; PMCID: PMC5978270.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 53 entries